SRRK ▲ +2.0% - Scholar Rock Holding Corporation $SRRK Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial Scholar Rock rose 2.0% after receiving FDA Fast Track designation for its apitegromab program in facioscapulohumeral muscular dystrophy, a rare genetic disorder. The company simultaneously announced the start of patient dosing in its Phase 2 FORGE trial, marking clinical progress in a rare disease indication with limited treatment options. 02-SEP-2026 08:00 AM ET